Effect of 21-gene recurrence score on chemotherapy decisions for patients with estrogen receptor-positive, epidermal growth factor receptor 2-negative and lymph node-negative early stage-breast cancer
10.3760/cma.j.issn.0253-3766.2017.07.005
- VernacularTitle: 21基因复发分数对雌激素受体阳性人表皮生长因子受体2阴性腋窝淋巴结阴性早期乳腺癌化疗决策的影响
- Author:
Yan MAO
1
;
Xiaosong CHEN
1
;
Yue LIANG
1
;
Jiayi WU
1
;
Ou HUANG
1
;
Yu ZONG
1
;
Qiong FANG
1
;
Jianrong HE
1
;
Li ZHU
1
;
Weiguo CHEN
1
;
Yafen LI
1
;
Lin LIN
2
;
Xiaochun FEI
3
;
Kunwei SHEN
1
Author Information
1. Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
2. Department of Clinical Laboratory, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
3. Department of Pathology, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai 200025, China
- Publication Type:Clinical Trail
- Keywords:
Breast neoplasms;
Antineoplastic combined chemotherapy protocols;
Receptors, estrogen;
Receptor, epidermal growth factor;
Lymph nodes;
21-gene recurrence score
- From:
Chinese Journal of Oncology
2017;39(7):502-508
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To investigate the effect of 21-gene recurrence score on adjuvant chemotherapy decisions for patients with estrogen receptor (ER)-positive, epidermal growth factor receptor 2 (HER-2)-negative and lymph node (LN)-negative early stage-breast cancer.
Methods:One hundred and forty-eight patients with ER+ , HER-2- and LN- early stage breast cancer were recruited in the Ruijin hospital, Shanghai Jiao Tong University School of Medicine. The 21-gene recurrence score (RS)assay was performed and systemic therapeutic decisions were made before and after knowing the RS results under multidisciplinary discussion. The effects of RS assay and the other influential factors on adjuvant chemotherapy decision were further analyzed.
Results:After knowing the RS results, treatment decisions were changed in 26 out of 148 patients(17.6%). Among them, 9 out of 26 patients were not recommended for chemotherapy; 16 of 26 had treatment recommendation changed to chemotherapy, and chemotherapy regimen was changed in the last one patient. Multivariate analysis showed that RS, age and histological grade were independent factors of decision-making for adjuvant chemotherapy.
Conclusion:Our results suggest that 21-gene recurrence score significantly influences decision making for adjuvant chemotherapy in patients with ER+ , HER-2- and LN- early stage breast cancer.
